Approximately 33 states representing 84% of Medicaid beneficiaries have adopted a Centers for Medicare & Medicaid Services (CMS) program enabling pay-for-performance arrangements with gene therapy manufacturers for products such as Casgevy and Lyfgenia. This initiative supports access to rare genetic therapies while incorporating outcome-based payment models to govern reimbursement under Medicaid.